PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:
Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen:
ONXEO), an innovative company specializing in the development of orphan oncology
therapeutics, today announced that senior management will present updates on the
Company’s advanced orphan oncology pipeline at the following upcoming investor
conferences:
· ODDO Biotech / Medtech Forum – March 31, 2016 in Paris (France)
· SFAF Journée Sectorielle Biotech – May 15, 2016 in Paris (France)
· Jefferies Healthcare Conference – June 7-10, 2016 in New York (U.S.A)
· European Large and Midcap Event – October 5-6, 2016 in Paris (France)
In addition, Onxeo will present at the following medical meetings:
· EASL, The International Liver Congress – April 13-17, 2016 in Barcelona
(Spain)
· AACR Annual Meeting 2016 – April 16-20, 2016 in New Orleans (U.S.A)
· ESTRO Annual Meeting 2016 – April 29-May 3, 2016 in Turin (Italy)
Onxeo’s next financial updates will be released on the following dates:
· Full-Year 2015 Results – February 26, 2016 (after the close of market)
· Full-Year 2015 Results and Company Update Analyst Conference Call – February
29, 2016 (6:30 PM CET; dial-in details to be released beforehand)
· Annual SFAF Meeting – March 7, 2016 (11:00 AM CET) in Paris (France)
Investors and analysts interested in scheduling a meeting with Onxeo management
or participating in a Company conference call can contact Onxeo’s Investor
Relations team (investors@onxeo.com) or Lee Roth and Joseph Green at The Ruth
Group (+1 646-536-7012/7013
or lroth@theruthgroup.com / jgreen@theruthgroup.com).
About Onxeo
Onxeo is a leading developer of orphan oncology drugs. The Company is focused on
developing innovative therapeutics for rare cancers, one of the fastest growing
markets in the healthcare industry with high, unmet medical needs. Onxeo’s
comprehensive portfolio features a broad orphan oncology pipeline, with three
independent programs in advanced clinical development, including Onxeo’s first
approved orphan oncology drug, Beleodaq®. In addition, Onxeo has successfully
developed and registered two non-cancer products which are currently being
commercialized in the U.S. and Europe. Onxeo’s vision is to become a global
leader and pioneer in oncology, with a focus on orphan or rare cancers, by
developing advanced, effective, and safe therapeutics designed to improve the
lives of patients. The Company is headquartered in Paris, France and has
approximately 50 employees. Onxeo is listed on Euronext in Paris, France
(Ticker: ONXEO, ISIN Code: FR0010095596) and NASDAQ Copenhagen, Denmark (Ticker:
ONXEO).
Onxeo orphan oncology products at the advanced development stage are:
· Livatag® (Doxorubicin Transdrug™): Currently being evaluated in a Phase III
trial (ReLive) in patients with hepatocellular carcinoma (primary liver cancer);
· Validive® (Clonidine Lauriad®): Positive final results from a Phase II trial
in head and neck cancer patients with severe oral mucositis;
· Beleodaq® (belinostat): FDA-approved in the U.S. in 2014 under the agency’s
accelerated approval program as a second-line treatment for patients with
peripheral T-cell lymphoma (PTCL) and currently marketed by Onxeo’s partner in
the U.S., Spectrum Pharmaceuticals; belinostat in combination with CHOP
(BelCHOP) is also in development as first-line treatment for patients with PTCL.
For more information, visit the
website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3
A
%2F%2Fwww.onxeo.com&esheet=51281569&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=1&md5=8e4ee63c5a7d9799ff668b422728a08a)
To receive our press releases and newsletters, please register
on: http://www.onxeo.com/en/newsletter/ (http://cts.businesswire.com/ct/CT?id=sm
a
rtlink&url=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&esheet=51281569&newsi
t
emid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&index=2&md5=d65533042
b
548a7e7029abf491d6d32b)
Follow us on Twitter: @Onxeo_
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference
Document filed with the AMF on April 14, 2015, which is available on the AMF
website (http://www.amf
-france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww
.
amf-france.org&esheet=51281569&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.amf
-france.org&index=3&md5=ac6508b17b047d49477a05885c7d003f)) or on the company’s
website
(www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F
w
ww.onxeo.com&esheet=51281569&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=4&md5=695f3a930075fb53d22cea60660670d5)).
Contacts
Onxeo
Investor Relations
Nathalie Delair-Trepo, + 33 1 45 58 76 00
investors@onxeo.com
or
Alize RP (France)
Caroline Carmagnol and Florence Portejoie, +33 6 64 18 99 59 / +33 6 47 38 90 04
onxeo@alizerp.com
or
The Ruth Group (U.S.)
Kirsten Thomas / Lee Roth, +1 508 280 6592 / +1 646 536 7012
kthomas@theruthgroup.com / lroth@theruthgroup.com
Onxeo to Attend Upcoming Investor Conferences and Medical Meetings
| Source: Onxeo SA
Attachments
